Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04949191
Title The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors Incyte Corporation
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | DNK


No variant requirements are available.